A Study to Investigate the Transmission and Burden of PVL-MRSA in Households in Sri Lanka
12 de maio de 2021 atualizado por: University of Sheffield
A Prospective Cohort Study to Investigate the Transmission and Burden of PVL-MRSA in Households in Sri Lanka
This study will determine the frequency of Staphylococcus aureus carriage in household contacts of individuals with clinical infection due to this pathogen.
It will also assess the frequency of transmission events over the following three months.
Finally it will aim to identify predisposing characteristics both on a demographic/social level as well virulence characteristics of the identified strains.
Visão geral do estudo
Status
Desconhecido
Condições
Descrição detalhada
This is a prospective cohort study based at Anuradhapura Teaching Hospital (Sri Lanka).
Potential index study participants will have clinical infection caused by Staphylococcus aureus and will be identified from hospital microbiology laboratory records within 48 hours of admission.
With consent, the investigators will approach up to 4 household members for participation in the carriage study.
With their consent, household members will have swabs collected on 2 occasions 3 months apart.
All hospitalised patients will receive standard-of-care treatment in accordance with local practice and national guidance.
Clinical, demographic and social/lifestyle data will be collected from index patients and households by scheduled interview performed by local investigators.
Bacterial isolates from the initial index patient infection, and those identified through household member screening will be assessed for antimicrobial susceptibility, virulence factor repertoire and analysed by whole genome sequencing.
While infection with the cc5 MRSA clone has been described in several hospital and hospital-associated settings in South Asia a major unresolved issue is whether transmission and circulation of this clone is occurring in community settings.
In this study the investigators will investigate and characterise the household circulation of Staphylococcus aureus strains, exploring differences in bacterial virulence characteristics and host susceptibility factors associated with increased risk of carriage.
Understanding these factors and estimating the burden of disease which may be occurring in the community setting will allow more accurate assessment of the risk posed by cc5 PVL-MRSA to similar Low and Middle Income Countries (LMIC) settings and signal potential routes to mitigation through treatment optimisation and disease prevention including infection control or vaccination.
Tipo de estudo
Observacional
Inscrição (Antecipado)
300
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos e mais velhos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Sim
Gêneros Elegíveis para o Estudo
Tudo
Método de amostragem
Amostra Não Probabilística
População do estudo
The index patients will have clinical infection due to Staphylococcus aureus identified during admission to Anuradhapura General Hospital.
The household contacts will be resident in the same household as the index patient so will be part of the local community served by Anuradhapura General Hospital.
Descrição
Inclusion Criteria (index patient):
- Confirmed clinical infection caused by Staphylococcus aureus infection, including skin and soft tissue infection (SSTI) or infection of a normally sterile site.
- Participant is willing and able to give informed consent for participation in the study.
- Male or Female greater or equal to 18 years old.
- Household is within one day's travel of the Hospital.
Inclusion Criteria (household contact):
- Resident in the same household as index participant.
- Participant is willing and able to give informed consent for participation in the study if greater or equal to 18 years old or the parent/legal guardian if participant is less than 18 years old.
- Likely continued household residence for at least 3 months from initial sample collection.
- Able to comply with study requirements.
Exclusion Criteria (index patient):
- Deemed unsuitable by the responsible clinical team/clinician (e.g. terminal illness).
Exclusion Criteria (household contact):
- Not a resident of the household at the time of the index patient hospital admission.
- Deemed unsuitable by the responsible clinical team/clinician (e.g. terminal illness)
- At least 4 household contacts already enrolled to this study.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
|---|
|
Index patient
Adults with confirmed clinical infection caused by Staphylococcus aureus, including skin and soft tissue infection or infection of a normally sterile site.
These cases will be identified following admission to Anuradhapura General Hospital.
|
|
Household contacts
This cohort are resident in the same household as the index patient (maximum of four).
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Determine the baseline prevalence of Staphylococcus aureus carriage or infection in household contacts of hospital inpatients diagnosed with clinical infection due to Staphylococcus aureus.
Prazo: First household visit and swabbing of household contacts will be as soon as possible after recruitment of the index case.
|
Index cases will be identified by screening laboratory reports for samples obtained within 72 hours of hospital admission and where Staphylococcus aureus has been isolated from a skin or soft tissue infection or a normally sterile site and there is a clinical diagnosis of infection at that site.
Up to 4 household contacts of this index case will be approached to participate in the study and will have bacterial swabs of the anterior nares and any incidental sites of infection at an initial assessment (as soon after identification and recruitment as possible).
The swabs will be inoculated on to blood agar and MacConkey agar.
Staphylococcus aureus will be identified by colonial morphology, Gram stain, catalase test and coagulase test.
Methicillin resistant Staphylococcus aureus will be detected by disc diffusion method using a cefoxitin disc as per the CLSI protocol.
|
First household visit and swabbing of household contacts will be as soon as possible after recruitment of the index case.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Measure the frequency of Staphylococcus aureus transmission events within households over a three month period.
Prazo: First visit and swabbing of the index and household contacts will be as soon as possible after recruitment of the index case. Both the index and household contacts will have a second visit 3 months later (window 2-4 months).
|
Proportion of household individuals carrying same/similar strains, as determined by similarity in antimicrobial susceptibility profile and genotypic homology.
This will be assessed over a three month time period to detect possible household transmission in contacts who are initially not detected as carriers.
|
First visit and swabbing of the index and household contacts will be as soon as possible after recruitment of the index case. Both the index and household contacts will have a second visit 3 months later (window 2-4 months).
|
|
Characterise predisposing clinical, demographic or social characteristic differences of individuals/households with evidence of household transmission over a three month period by interview and completion of a proforma.
Prazo: The baseline interviews will occur as soon as possible after the index patient is recruited and the second interview will occur three months later (window 2-4 months).
|
After consent is obtained, study investigators will visit the dwellings to assess up to 4 household contacts.
A baseline interview using a proforma will be conducted to investigate each individual and their shared dwellings.
This will include identification of: dwelling location, type of dwelling, number of other inhabitants, pet/animal ownership, occupations, duration of residence, recent illness/hospitalisations, recent courses of antimicrobial treatment.
This will be repeated at the follow up visit to ensure there have not been any change in circumstances.
|
The baseline interviews will occur as soon as possible after the index patient is recruited and the second interview will occur three months later (window 2-4 months).
|
|
Describe virulence characteristics of strains causing a) (invasive) infection and b) higher number of household transmission events
Prazo: Data analysis will occur throughout and beyond the study recruitment period, expected to take a minimum of 6 months.
|
Analysis of whole genome sequencing and antimicrobial virulence data from isolates that are more associated with infection (in the index and household contacts) and where a high frequency of household transmission has been observed.
|
Data analysis will occur throughout and beyond the study recruitment period, expected to take a minimum of 6 months.
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Thomas Darton, University of Sheffield
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Antecipado)
1 de maio de 2021
Conclusão Primária (Antecipado)
1 de julho de 2021
Conclusão do estudo (Antecipado)
1 de setembro de 2021
Datas de inscrição no estudo
Enviado pela primeira vez
3 de março de 2021
Enviado pela primeira vez que atendeu aos critérios de CQ
12 de maio de 2021
Primeira postagem (Real)
13 de maio de 2021
Atualizações de registro de estudo
Última Atualização Postada (Real)
13 de maio de 2021
Última atualização enviada que atendeu aos critérios de controle de qualidade
12 de maio de 2021
Última verificação
1 de março de 2021
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- 164460
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
INDECISO
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .